As part of our coverage of the 2018 GI Cancers Symposium, we discussed the role of locoregional therapies for patients with metastatic esophageal and gastric cancers.
In this interview we discuss a study that examined the risk of acute myeloid leukemia in thyroid cancer patients who have been treated with surgery and radioiodine therapy vs those treated with surgery alone.
Developments in Breast Cancer 2017–2018: New Drugs, New Drug Classes—and the Prospect of More to Come
This interview provides perspective on developments in breast cancer treatment in 2017, as well as a preview of what we can expect to change in the treatment of breast cancer in 2018.
In this interview we discuss the goals of SIO, the response to donations intended for interdisciplinary integrative health, and how palliative care and psychosocial oncology can enhance each other.
In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.
In this interview we discuss a retrospective study that looked at survival outcomes in HPV-positive oropharyngeal cancer patients treated with either definitive chemoradiation therapy or primary surgery.
In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
In this interview we discuss the STOPCaP trial, a meta-analysis that looked at optimal systemic therapy options for men with metastatic hormone-sensitive prostate cancer.
In this interview we discuss health disparities in cancer care, how redesigning cancer clinical trials can address some of these disparities, and goals for the “next generation” of cancer health disparities research.
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.